---
document_datetime: 2023-09-21 19:13:38
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/silgard-epar-procedural-steps-taken-authorisation_en.pdf
document_name: silgard-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5323135
conversion_datetime: 2025-12-20 09:28:23.436385
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Merck Sharp &amp; Dohme Ltd., submitted on 04 April 2006 an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Silgard,  through  the  centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

## The application submitted is a complete dossier:

composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Bengt Ljungberg

Co-Rapporteur:

Eric Abadie

## Scientific Advice:

The applicant received Scientific Advice from the CHMP on 21 January 2004. The Scientific Advice pertained to clinical aspects of the dossier.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 04 April 2006.
- The procedure started on 27 April 2006. This application forms part of a multiple application for Human Papillomavirus Vaccine Quadrivalent [ Types 6, 11, 16,18 ] , Recombinant, Adsorbed. The initial  application  was  submitted  by  Sanofi  Pasteur  MSD  (EMEA/H/C/703).  The  review process  for  both  applications  were  integrated  at  the  time  of  List  of  Questions,  allowing  the CHMP opinion to be adopted in the same timeframe as EMEA/H/C/703.
- During  the  meeting  on  24-27  April  2006  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 27 April 2006.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 18 May 2006.
- The Rapporteurs circulated the D150 Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 30 June 2006.
- The Vaccine Working Party during its meeting of 4-6 July 2006 adopted a VWP Report to be transmitted to the CHMP for endorsement.
- The Biologics Working Party during its meeting of 17-19 July 2006 adopted a BWP Report to be transmitted to the CHMP for endorsement.

<div style=\"page-break-after: always\"></div>

- The Rapporteurs circulated the D180 Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 20 July 2006.
- During the meeting on 24-27 July 2006 the CHMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Silgard  on  27  July  2006.  The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 27 July 2006.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 20 September 2006.